Gynaecomastia in men with chronic myeloid leukaemia after imatinib.
cKit and platelet-derived growth-factor receptor (PDGFR) are receptor tyrosine kinases expressed in the testis, are involved in testosterone production, and are inhibited by imatinib. We measured hormone concentrations in 38 men receiving imatinib for chronic myeloid leukaemia at baseline and during treatment. Mean follow-up was 23.6 months (SD 7.5). We noted seven cases of gynaecomastia (18%, 95% CI 6-30%). A comparison of hormone concentrations in 21 patients before and during treatment showed that patients who developed gynaecomastia had a reduction in free testosterone concentrations of 29.53 pmol/L (95% CI 11.63-47.43), while patients who did not had a decrease of 6.36 pmol/L (-1.02 to 13.74). In most men with chronic myeloid leukaemia studied here, imatinib was associated with a reduction in the production of testicular hormones and in some, with the development of gynaecomastia.
Gambacorti-Passerini
Carlo
C
National Cancer Institute, Milan, Italy. carlo.gambacorti@istitutotumori.mi.it <carlo.gambacorti@istitutotumori.mi.it>
Tornaghi
Lucia
L
Cavagnini
Francesco
F
Rossi
Pellegrino
P
Pecori-Giraldi
Francesca
F
Mariani
Luigi
L
Cambiaghi
Nadia
N
Pogliani
Enrico
E
Corneo
Gianmarco
G
Gnessi
Lucio
L
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D006177:Gynecomastia / Q000139:chemically induced*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011374:Progesterone / Q000097:blood; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D013739:Testosterone / Q000097:blood
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013739:Testosterone; D011374:Progesterone; D000068877:Imatinib Mesylate